Tradjenta (Boehringer) shows no added benefit in assessment for Type 2 Diabetes

In a review, the German Institute for Quality and Efficiency in Health Care (the institute that investigates the benefits and harms of medical interventions for patients) has found that the added benefit of the Type 2 Diabetes drug Tradjenta (linagliptin), from Boehringer, is not proven since the drug manufacturer deviated from appropriate comparator therapy specified by the Federal Joint Committee in its assessment. The manufacturer compared Tradjenta with a different drug from the gliptin class (sitagliptin) in three treatment situations specified by the IQWiG. Thus it provides no proof of added benefit of Tradjenta versus monotherapy as a substitute for metformin, dual (combining Tradjenta and metformin) and triple combination (Tradjenta, metformin and a sulfonylurea) therapy.